Amphastar Pharmaceuticals Operating Income 2012-2026 | AMPH
Amphastar Pharmaceuticals operating income from 2012 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
Amphastar Pharmaceuticals Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $140 |
| 2024 | $205 |
| 2023 | $197 |
| 2022 | $107 |
| 2021 | $70 |
| 2020 | $11 |
| 2019 | $0 |
| 2018 | $-9 |
| 2017 | $-1 |
| 2016 | $15 |
| 2015 | $-7 |
| 2014 | $-18 |
| 2013 | $17 |
| 2012 | $25 |
| 2011 | $-34 |
|
Amphastar Pharmaceuticals Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $40 |
| 2026-03-31 | $14 |
| 2025-12-31 | $36 |
| 2025-09-30 | $25 |
| 2025-06-30 | $42 |
| 2025-03-31 | $37 |
| 2024-12-31 | $45 |
| 2024-09-30 | $57 |
| 2024-06-30 | $55 |
| 2024-03-31 | $48 |
| 2023-12-31 | $54 |
| 2023-09-30 | $73 |
| 2023-06-30 | $37 |
| 2023-03-31 | $33 |
| 2022-12-31 | $38 |
| 2022-09-30 | $23 |
| 2022-06-30 | $25 |
| 2022-03-31 | $22 |
| 2021-12-31 | $24 |
| 2021-09-30 | $25 |
| 2021-06-30 | $11 |
| 2021-03-31 | $10 |
| 2020-12-31 | $3 |
| 2020-09-30 | $4 |
| 2020-06-30 | $-3 |
| 2020-03-31 | $7 |
| 2019-12-31 | $0 |
| 2019-09-30 | $2 |
| 2019-06-30 | $1 |
| 2019-03-31 | $-3 |
| 2018-12-31 | $2 |
| 2018-09-30 | $3 |
| 2018-06-30 | $-3 |
| 2018-03-31 | $-10 |
| 2017-12-31 | $-2 |
| 2017-09-30 | $-3 |
| 2017-06-30 | $2 |
| 2017-03-31 | $1 |
| 2016-12-31 | $-5 |
| 2016-09-30 | $6 |
| 2016-06-30 | $10 |
| 2016-03-31 | $4 |
| 2015-12-31 | $14 |
| 2015-09-30 | $-4 |
| 2015-06-30 | $-10 |
| 2015-03-31 | $-7 |
| 2014-12-31 | $-7 |
| 2014-09-30 | $-8 |
| 2014-06-30 | $-1 |
| 2014-03-31 | $-2 |
| 2013-12-31 | $3 |
| 2013-09-30 | $0 |
| 2013-06-30 | $12 |
| 2013-03-31 | $2 |
| 2012-12-31 | $52 |
| 2012-09-30 | $57 |
| 2012-06-30 | $49 |
| 2012-03-31 | $46 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.019B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |